Drugs for Alzheimer's disease: Are they effective?

P and T

Volumn 35, Issue 4, 2010, Pages 208-211

  Casey, David A ^a   Antimisiaris, Demetra ^b   O'Brien, James ^b,c  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b The University   (United States)

^c Department of Family and Geriatric Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GLUTAMIC ACID; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO; RIVASTIGMINE; TACRINE;

ADD ON THERAPY; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE; BRADYCARDIA; CAUSE OF DEATH; CLINICAL TRIAL; CLINICIAN'S INTERVIEW BASED IMPRESSION OF CHANGE; COGNITIVE DEFECT; COST BENEFIT ANALYSIS; DEMENTIA; DIARRHEA; DISEASE SEVERITY; DRUG APPROVAL; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; ENZYME DEGRADATION; GASTROINTESTINAL SYMPTOM; HUMAN; MINI MENTAL STATE EXAMINATION; MUSCLE WEAKNESS; NAUSEA; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPSYCHIATRIC INVENTORY; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; PSYCHOMETRY; RATING SCALE; REVIEW; SIDE EFFECT; SLEEP DISORDER; SYNCOPE; WEIGHT REDUCTION;

EID: 77957150679     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Alzheimer's Association. 2009 Alzheimer's Disease Facts and Figures. Available at: www.alz.org/alzheimers-disease-facts-figures.asp; report-alzfactsfigures2009.pdf; and www.alz.org/news-and-events-2009-facts- figures.asp. Accessed February 8, 2010.
2. Larson EB, Shadlen M, Wang L, et al. Survival after initial diagnosis of Alzheimer's disease. Ann Intern Med 2004;140(7):501-509.
3. Qaseem A, Snow V, Cross T, et al. Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008;148(5):370-378.
4. Grady D. Finding Alzheimer's before a mind fails. The New York Times, December 26, 2007, p. A1.
5. Mount C, Downton C. Alzheimer disease: Progress or profit? Nat Med 2006;12(7):780-784.
6. Frierson RL. Dementia, delirium, and other cognitive disorders. In: Tasman A, Kay J, Lieberman JA, et al., eds. Psychiatry, 3rd ed. West Sussex, U.K: Wiley; 2008:897-930.
7. Schnabel J. Another Alzheimer's drug fails in large-scale trials: Flurizan's maker says it will discontinue work on the drug. The Dana Foundation, June 30, 2008. Available at: www.dana.org/news/features/detail.aspx?id=12742. Accessed February 4, 2010.
8. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006(1):CD005593.
9. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006(1):CD001190.
10. Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev 2005(3):CD003154.
11. Jackson S, Ham RJ, Wilkinson D. The safety and tolerability of donepezil in patients with Alzheimer's disease. Br J Clin Pharmacol 2004;58:1-8.
12. Winblad B, Poritis N. Memantine in severe dementia: Results of the 9M-BEST Study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-146. (Pubitemid 29110331)
13. Orgogozo JM, Rigaud AS, Stoffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: A randomized, placebo-controlled trial. Stroke 2002;17:297-305. (Pubitemid 35283717)
14. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 2004;291:317-324. (Pubitemid 38101604)
15. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141(11):1356-1364.
16. Folstein MF, Folstein SE, McHugh PR. 'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
17. Knopman DS, Knapp MJ, Gracon SI, et al. The Clinician Interview-Based Impression (CIBI): A clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44(12):2315-2321.
18. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994;44(12):2308-2314. (Pubitemid 24382728)
19. Molnar FJ, Hutton B, Fergusson D. Does analysis using 'last observation carried forward' introduce bias in dementia research? Can Med Assoc J 2008;179(8):751-753.
20. Geldmacher DS, Provenzano G, McRae T, et al. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003;51(7):937-944. (Pubitemid 36871141)
21. Howard RJ, Juszczak B, Ballard, CG, et al. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007;357(14):1382-1392.
22. National Institute for Clinical Excellence (NICE). Alzheimer's disease: Donepezil, galantamine, rivastigmine (review) and memantine. Available at: www.nice.org.uk/guidance/TA111. Accessed February 2, 2010.
23. Vernon J, Goldberg R, Dash Y, Muralimohan G. Alzheimer's disease and cost-effectiveness analyses: Ensuring good value for money? ACT-AD (Accelerate Cure/Treatments for Alzheimer's Disease), May 2007. Available at: www.act-ad.org/pdf/Study-Final-051407.pdf. Accessed February 2, 2010.
24. Warner J. Drugs for Alzheimer's disease. BMJ 2001; 323(7321):1127.
25. Gilstad JR, Finucane TE. Results, rhetoric, and randomized trials: The case of donepezil. J Am Geriatr Soc 2008;56(8):1556-1562.
26. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Alzheimer's Disease and Other Dementias, 2nd ed. Am J Psychiatry 2007;164(12 Suppl):)5-56.
27. Qaseem A, Snow V, Cross JT, et al. Current pharmacologic treatment of dementia: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008;148(5):370-378. ■